The Global Action Plan for Healthy Lives and Well-being for All (SDG3 GAP) is a set of commitments by 13 multilateral agencies to strengthen their collaboration. For this purpose several accelerators were created and an invitation for public comment was started. This document focuses on Accelerator ...Discussion Paper 1: Sustainable Financing.
more
World Health Organization. Regional Office for South-East Asia
World Health Organization. Regional Office for South-East Asia.
World Health Organization. Regional Office for South-East Asia
This checklist is an operational tool to help national authorities develop or revise national respiratory pathogen (inclusive of influenza and coronaviruses) pandemic preparedness plans.
HIV epidemic and response in Latin America and the Caribbean: PPT
At the moment, 83 elderly people are receiving care in six round-the-clock care facilities, 17 of them are from the Stepanakert nursing home, 50 are single. As of September 24, 10 children, 5 girls and 5 boys, aged 1 to 17, living in Stepanakert boarding house were also transferred to a round-the-cl...ock care facility on September 25. All children have biological parents.
more
Le programme des services de santé communautaire sert de programme phare pour la prestation des soins de
santé primaires en Éthiopie. Cependant, sa mise en œuvre s’est heurtée à divers obstacles au niveau du système
de santé. En présentant des stratégies porteuses de transformation, la... feuille de route pour l’optimisation
du programme des services de santé communautaire (2020-2035) offre une occasion de restructurer et de
normaliser l’approche de prestation de services du programme afin d’en assurer la durabilité et l’impact à long
terme
more
To address the health challenges brought about by the changing food environment and high salt intake, WHO China, jointly with the National Institute for Nutrition and Health of China CDC and Tsinghua University, conducted an innovative study that applied nudge-based interventions to promote lower sa...lt dish options on a Chinese meal delivery app in 2020-2022.
more
This report describes the results of the Lao People's Democratic Republic (LAO PDR) National WASH Survey 2021. The survey examined water, sanitation and hygiene (WASH) and waste management services, as well as climate resilience, in Lao PDR health-care facilities. The survey reveals that while... most facilities (70%) have basic water services, there are significant gaps in the delivery of sanitation, hygiene and health-care waste services, and few facilities are climate resilient, despite a majority being impacted by extreme weather events. Based on these results, the report presents a monitoring framework and national- and HCF-level measures to further enhance WASH services and climate resilience in the country.
more
According to the 2016 Nepal Demographic and Health Survey, 66% of Nepali households use mainly solid fuel for cooking on inefficient stoves. Incomplete fuel combustion of solid fuels emits greenhouse gases and harmful smoke, contributing to climate change, forest degradation, ill health and preventa...ble deaths. Further, the physical burden and time necessary to collect wood for fuel is borne primarily by women and children, thus compromising their productive time, such as social activities and education.
more
This updated manual provides a basic understanding of the principles of laboratory and point-of-care (POC) testing in the context of screening and diagnostic approaches, as well as antimicrobial susceptibility testing, as components of sexually transmitted infections (STIs) control. As with previous... editions, this manual covers each disease in a separate chapter which provides detailed information on specimen collection, transport and laboratory testing. Two useful annexes covering media, reagents, diagnostic tests and stains (recipes) and laboratory supplies are included at the end of the manual.
more
World Health Organization. Country Office for Timor-Leste. (2020). National strategic plan for ending TB 2020--2024. World Health Organization. Country Office for Timor-Leste.
Response to the Periodic Epidemic
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19.
The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients.
This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines:
**High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%.
**Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%.
Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk.
Review of COVID-19 treatments for people with non-severe COVID-19
WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022.
If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead.
WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission.
For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol.
WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials.
The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials.
more
This document summarizes several air quality measurement and modelling methods that can be used to estimate ground-level air pollutant concentrations and presents multiple approaches to monitoring ambient air pollution at different spatial and temporal scales. These methods are crucial for estimatin...g population exposures, which can be defined as the product of the pollutant concentration and the time over which a person is in contact with this pollutant.
more
Prompt, effective antimalarial treatment, and supportive care can substantially reduce the rate of mortality from severe malaria. However, many children in malaria-endemic countries do not have access to health facilities or a qualified health care provider and do not receive the necessary care in a... timely fashion. Without rapid detection of danger signs and access to effective treatment, including pre-referral treatment that can be administered in the community level, many of these children with severe malaria die.
In situations where there is no immediate access to a health care facility, WHO recommends the administration of a standard dose of an effective antimalarial medicine as pre-referral treatment before referral to a facility at which complete treatment can be administered.
Rectal artesunate is the WHO-recommended pre-referral intervention in situations where artesunate injection are not feasible for children under the age of 6 years with suspected severe malaria. The intervention reduces the risk of death or permanent disability by up to 50% provided the child is referred to a health facility at which complete treatment can be administered.
This field guide is aimed at supporting the effective deployment of RAS as pre-referral treatment of suspected severe malaria in line with the WHO malaria guidelines.
more